Caliway Biopharmaceuticals Co Ltd (6919) Stock Statistics & Valuation Metrics
Total Valuation
Caliway Biopharmaceuticals Co Ltd has a market cap or net worth of TWD 99.66B. The enterprise value is TWD 150.69B.
- Market Cap
- TWD 99.66B
- Enterprise Value
- TWD 150.69B
Share Statistics
Caliway Biopharmaceuticals Co Ltd has 1,557,200,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,557,200,800
- Owned by Insiders
- ―
- Owned by Institutions
- 4.15%
Financial Efficiency
Caliway Biopharmaceuticals Co Ltd’s return on equity (ROE) is -1.17 and return on invested capital (ROIC) is -234.94%.
- Return on Equity (ROE)
- -1.17
- Return on Assets (ROA)
- -1.16
- Return on Invested Capital (ROIC)
- -234.94%
- Return on Capital Employed (ROCE)
- -2.35
- Revenue Per Employee
- 1.90M
- Profits Per Employee
- -17.57M
- Employee Count
- 20
- Asset Turnover
- 0.13
- Inventory Turnover
- 3.99
Valuation Ratios
The current PE Ratio of Caliway Biopharmaceuticals Co Ltd is -176.13. Caliway Biopharmaceuticals Co Ltd’s PEG ratio is 0.95.
- PE Ratio
- -176.13
- PS Ratio
- 6807.21
- PB Ratio
- 12.14
- Price to FCF
- -262.04
- Price to Operating Cash Flow
- -268.21
- PEG Ratio
- 0.95
Income Statement
In the last 12 months, Caliway Biopharmaceuticals Co Ltd had revenue of 37.98M and earned -351.35M in profits. Earnings per share was -0.23.
- Revenue
- 37.98M
- Gross Profit
- 26.48M
- Operating Income
- -706.09M
- Pretax Income
- -351.35M
- Net Income
- -351.35M
- EBITDA
- -675.43M
- Earnings Per Share (EPS)
- -0.23
Cash Flow
In the last 12 months, operating cash flow was -280.99M and capital expenditures -19.89M, giving a free cash flow of -300.88M billion.
- Operating Cash Flow
- -280.99M
- Free Cash Flow
- -300.88M
- Free Cash Flow per Share
- -0.27
Dividends & Yields
Caliway Biopharmaceuticals Co Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.38%
- Earnings Yield
- -0.57%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- -56.16%
- 50-Day Moving Average
- 77.64
- 200-Day Moving Average
- 104.09
- Relative Strength Index (RSI)
- 33.86
- Average Volume (3m)
- 7.00M
Important Dates
Caliway Biopharmaceuticals Co Ltd upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 03, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Caliway Biopharmaceuticals Co Ltd as a current ratio of 109.71, with Debt / Equity ratio of 0.03%
- Current Ratio
- 109.71
- Quick Ratio
- 107.72
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.04
- Interest Coverage Ratio
- -4534.35
Taxes
In the past 12 months, Caliway Biopharmaceuticals Co Ltd has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Caliway Biopharmaceuticals Co Ltd EV to EBITDA ratio is -97.30, with an EV/FCF ratio of -256.34.
- EV to Sales
- 6659.18
- EV to EBITDA
- -97.30
- EV to Free Cash Flow
- -256.34
- EV to Operating Cash Flow
- -267.67
Balance Sheet
Caliway Biopharmaceuticals Co Ltd has TWD 4.05B in cash and marketable securities with TWD 107.95M in debt, giving a net cash position of TWD 3.94B billion.
- Cash & Marketable Securities
- TWD 4.05B
- Total Debt
- TWD 107.95M
- Net Cash
- TWD 3.94B
- Net Cash Per Share
- TWD 2.53
- Tangible Book Value Per Share
- TWD 5.94
Margins
Gross margin is -109.70%, with operating margin of -6990.12%, and net profit margin of -3831.58%.
- Gross Margin
- -109.70%
- Operating Margin
- -6990.12%
- Pretax Margin
- -3831.58%
- Net Profit Margin
- -3831.58%
- EBITDA Margin
- -6843.66%
- EBIT Margin
- -6990.12%
Analyst Forecast
The average price target for Caliway Biopharmaceuticals Co Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -54.34%
- EPS Growth Forecast
- -25.60%
